"Successful investing takes time, discipline, and patience. No matter how great the talent or effort, some things just take time", said Warren Buffett. The question now is - did you have the patience to hold on to stocks we highlighted and reap the gains? Cidara Therapeutics Inc. (CDTX) touched a 52-week high of $87.19 today, as it continues to progress with its accelerated development plan for CD388, a non-vaccine preventive treatment for seasonal influenza. The company will be pursuing a Biologics Licens ...

We came across a bullish thesis on Maze Therapeutics, Inc. on deep market scan subreddit by retroviber. In this article, we will summarize the bulls’ thesis on MAZE. Maze Therapeutics, Inc.'s share was trading at $23.25 as of September 15th. MAZE’s forward P/E was 8.53 according to Yahoo Finance. Tempus AI (TEM) Initiated at ‘Buy’ with $60 Price Target by BTIG Sergey Nivens/Shutterstock.com Maze Therapeutics (NASDAQ: MAZE) is showing a compelling move in the small-cap biotech space, driven by a rare com ...

Investing in biotechnology stocks is complex due to the science behind the company’s drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence. However, biotech stocks offer a compelling risk-reward proposition as a long-term investment. The payoff in these three stocks can be massive for investors with the patience and time to hold them through the clinical trial phase.  Get Maze Therapeutics alerts:Viking: An Ob ...

武田制药高管任命 - 罗恩达·帕切科将于9月29日接任武田美国业务部门负责人 她此前在礼来担任心血管代谢健康部门集团副总裁 负责GLP-1药物的商业化推广[2] - 朱莉·金将于2026年6月接替退休的克里斯托夫·韦伯出任首席执行官 过渡期间将临时负责公司全球产品组合[2] Maze Therapeutics药物研发进展 - 公司股价因苯丙酮尿症药物早期数据上涨超50% 口服药物MZE782在1期试验中所有剂量均耐受良好 未报告严重不良事件[2] - 治疗使关键氨基酸尿液水平超出投资者预期 Leerink Partners分析师认为该药物具备"最佳临床潜力"[2] - 公司同步宣布完成1.5亿美元私募配售[2] Intercept Pharmaceuticals市场撤市 - 应FDA要求撤回肝病药物Ocaliva在美国市场的销售 该药物于2016年获批用于原发性胆汁性胆管炎[2] - FDA要求暂停所有涉及Ocaliva的临床试验 该药物2018年被加注黑框警告 去年12月被提示存在额外肝损伤风险[2] - 公司多年尝试将Ocaliva用于代谢性疾病MASH的申请均未获批准 已于2023年被意大利Alfasigma收购[2] Soleno Therapeutics安全事件影响 - 公司股价下跌近20% 因Prader Willi综合征治疗药物Vykat在FAERS系统中报告患者死亡事件[2] - 公司强调治疗医师认为死亡与药物无关 FAERS报告不构成因果关系 患者死因为血栓栓塞且存在既往健康问题[2] - Stifel分析师认为事件细节强烈支持与药物无关 对公司股价波动表示意外[2] - 公司股价自上月做空机构Scorpion Capital发布安全质疑报告以来已下跌约三分之一[2]

PresentationAmy Bachrodt Good morning, everyone, and thank you for joining us today for Maze's event on data from the Phase I clinical trial of MZE782, an oral SLC6A19 inhibitor with potential to treat phenylketonuria or PKU in chronic kidney disease or CKD. [Operator Instructions]. As a reminder, this conference call is being recorded. Before we start, I would like to remind you that today's event, which is intended for the investment community, will include forward-looking statements based on current expe ...

Maze Therapeutics, Inc. MAZE on Thursday shared clinical results from the Phase 1 healthy volunteer study of MZE782, an oral small molecule targeting the solute transporter, SLC6A19.MZE782 has the potential to be a best-in-class therapy for patients with phenylketonuria (PKU), an inherited metabolic disorder, and a first-in-class therapy for chronic kidney disease (CKD).MAZE is reaching significant price levels. See the full breakdown here.Pharmacokinetics (PK)MZE782 demonstrated a favorable plasma PK profi ...

BREAKING: Core CPI Steady, Jobless Claims Highest Since Oct. 2021Shares of Maze Therapeutics (MAZE) catapulted Thursday after its experimental treatment for a rare, genetic disease blew past the company's own expectations.Leerink Partners analyst Joseph Schwartz said Maze could have a best-in-class treatment for phenylketonuria, or PKU. In this condition, the body can't break down phenylalanine, an essential amino acid. The buildup of phenylalanine can lead to intellectual disability, seizures, small head s ...

Maze Therapeutics Harnessing the power of human genetics to transform the lives of patients Phase 1 Results September 11, 2025 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than statements of historical fact are statements that could be deemed forward-loo ...

融资概况 - 公司宣布达成证券购买协议，进行超额认购的私募配售，总收益约为1.5亿美元，需扣除配售代理费及其他费用 [1] - 私募配售预计于2025年9月12日完成，需满足惯例交割条件 [4] 投资者与发行条款 - 私募配售获得新老投资者参与，包括Frazier Life Sciences、Deep Track Capital、Driehaus Capital Management、Janus Henderson Investors、Logos Capital、TCGX及Venrock Healthcare Capital Partners等专注于医疗保健的基金 [2] - 私募发行4,000,002股普通股，每股价格16.25美元，较前一收盘价存在溢价；部分投资者购买5,231,090份预融资权证，每份价格16.249美元，等于普通股购买价减去每份0.001美元的行使价，该权证可于发行后随时行使且无到期日 [3] - 联合配售代理机构包括摩根大通、Leerink Partners、TD Cowen和Guggenheim Securities [5] 资金用途 - 公司计划将本次私募所得款项与现有现金及现金等价物和短期投资一并用于推进APOL1介导肾病药物MZE829的研发、启动MZE782在苯丙酮尿症和慢性肾病中的二期临床试验、继续推进研发与发现项目、进一步发展其Compass平台以及用于营运资金和其他一般公司用途 [4] 公司业务与管线 - 公司是一家临床阶段生物制药公司，致力于利用人类遗传学为肾脏及代谢疾病患者开发新型小分子精准药物 [8] - 公司主要管线包括用于APOL1介导肾病的双重机制APOL1抑制剂MZE829（处于二期研发阶段），以及用于治疗苯丙酮尿症和慢性肾病的SLC6A19抑制剂MZE782（即将进入二期临床试验） [8]

Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid excretion demonstrated across all SAD and MAD cohorts, including up to a 42-fold increase in urinary phenylalanine (Phe) excretion, a well-validated biomarker for PKU and predictive for CKD Dose-dependent initial eGFR dip similar to SGLT2 inhibitors observed, supporting a potential kidney protective effect in C ...